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aCentre for Public Health, Queen’s University Belfast, Belfast, UK
bCentre for Medical Education, Queen’s University of Belfast, Belfast, UK
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Abstract Introduction: Oxidative stress has been implicated in the pathogenesis of Alzheimer’s disease (AD).
We investigated associations between serum levels of lipophilic antioxidants and AD.
Methods: Serum concentrations of retinol, two forms of vitamin E (a- and g-tocopherol) and six
carotenoids were quantified by high-performance liquid chromatography from patients with AD
(n 5 251) and cognitively intact controls (n 5 308) and assessed by regression analyses.
Results: Serum levels of a-tocopherol and all six carotenoids were significantly lower in patients
with AD compared with cognitively intact controls (P, .001). In contrast, g-tocopherol was signif-
icantly higher in the serum of patients with AD (odds ratio5 1.17 [confidence intervals: 1.05–1.31]).
Discussion: Our findings implicate compromised serum antioxidant defenses in AD pathogenesis
and differing biological roles for vitamin E isoforms. This highlights the need for improved under-
standing in the balanced upregulation of exogenous antioxidants related to dietary intake or supple-
ment use in future nutritional intervention studies.
 2017 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).
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1. Introduction
Alzheimer’s disease (AD) is the most common dementia
subtype accounting for approximately 75% of all cases [1].
Multiple neuropathological processes underlie the onset of
cognitive decline leading to disease, a process likely influ-
enced by a range of both modifiable and nonmodifiable
risk factors [2].
Among the etiological processes proposed, there is
increasing support for oxidative injury and inflammatory
damage early in AD pathogenesis [3–5]. The brain is
especially vulnerable to reactive oxygen species due to
neurons possessing relatively low levels of endogenous
antioxidants to cope with their high metabolic activity.
This antioxidant deficit results in oxidative damage to
major cell components with elevated levels of
inflammatory markers resulting in neuronal cell death [4].
Nutritional influences in ADmay provide significant pub-
lic health benefit, but the influence of dietary antioxidants on
AD risk remains unclear. Plausible mechanisms by which
nutritional factors such as serum carotenoids and vitamins
may reduce cognitive decline have been proposed, such as
antioxidative and/or anti-inflammatory processes, including
those common to vascular and nonvascular diseases [6].
Despite numerous studies examining a variety of antiox-
idants, the most recent systematic review of serum antiox-
idant status in AD reported the overall quality of evidence
to be low, due to insufficient control for potential con-
founders in studies with low power producing inconsistent
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findings, and also due to the relative absence of random-
ized control trials [7]. We sought to address these limita-
tions through increased sample size with adjustment of
effect estimates for potential confounding variables. We
compared serum retinol, a-tocopherol, and g-tocopherol
(referred to as antioxidant vitamins) as well as the six ma-
jor carotenoids found in considerable concentrations in
serum: lutein, zeaxanthin, b-cryptoxanthin, a-carotene,
b-carotene, and lycopene in patients with AD and cogni-
tively intact controls. We sought to evaluate any associa-
tions between levels of exogenous antioxidants in sera of
participants with AD risk.
2. Methods
2.1. Study population
This was a prevalent case-control study in which cases
with AD were compared to cognitively intact controls.
All recruitment and testing were performed by one investi-
gator (M.A.W.) from August 2006 to 2008 and has been
described elsewhere [8]. Methods reported were guided
as far as possible by STROBE guidelines for case-control
studies [9]. Cases and controls were not matched. The po-
wer calculation for sample size was based on a genetic
outcome of interest, reported elsewhere [10]. Potential
AD cases were identified as they appeared in the memory
clinic in Belfast City Hospital, UK and Knockbracken
Healthcare Park, UK or from records of previous attendees
in the same clinics. AD was defined as per the diagnosis of
a senior clinician using the National Institute of Neurolog-
ical and Communicative Disorders and Stroke and the Alz-
heimer’s Disease and Related Disorders Association
(NINCDS ADRDA) criteria [11]. Exclusion criteria were
being diagnosed with other types of dementia, including
vascular or mixed dementia, applied to ensure as far as
feasible the cases consisted of AD cases only. The carer
was approached in person or by phone, an opportunity
given for the carer and patient to ask questions and permis-
sion sought to contact them again. After at least 24 hours to
read the information sheet, carers were contacted, and if
they and the person with AD were willing to participate,
the study visit was arranged.
The recruitment strategies used in the enrollment of con-
trols were designed to identify enough cognitively normal
individuals in a practical manner. First, carers of patients
attending any outpatient clinic in the study hospitals were
approached. Second, a university press release invited
participation in the study. Third, a series of talks given to
AD patient-support groups in the region led to further volun-
teers coming forward. Fourth, controls asked their friends
and relatives to participate. Exclusion criteria for controls
included age under 65 years, to mirror if not formally match
cases’ ages, a Mini–Mental State Examination (MMSE)
score of below 26 of 30 to try to exclude undiagnosed AD
cases from being controls, or any history of neurological dis-
ease or dementia. After the study visit, there was no follow-
up for cases or controls.
Ethics and clinical governance approval was obtained
before commencement of the study which adhered to the te-
nets of the Declaration of Helsinki. On enrollment, all study
participants underwent an assessment that involved drawing
a blood sample, measuring blood pressure, and performing a
MMSE. The final component of the assessment involved the
completion of questionnaires via interviews with the subject,
as well as their carer when appropriate.
2.2. Detection of serum dietary antioxidants
Serum samples were coded and stored at 280C for
extraction and batch analysis in a blinded fashion. Serum
concentrations of retinol, a-tocopherol, g-tocopherol, and
six carotenoids (a-carotene, b-carotene, b-cryptoxanthin,
lutein, lycopene, zeaxanthin) were determined by high-
performance liquid chromatography (HPLC) with diode
array detection [12].
Chromatograms were analyzed using ChromQuest 4.2
software (Thermo Fisher Scientific, MA, USA). The mobile
phase consisted of 97% methanol/3% tetrahydrofuran with
solvents degassed using an in-line degasser before the
HPLC pump. The flow rate was 1 mL/minute and the column
was maintained at 31C. The HPLC components were all
ThermoSeparation Products allowing for the simultaneous
detection of three wavelengths of magnitude 325, 292, and
450 nm.
All analytes were quantified using external standards
(Sigma-Aldrich, Poole, Dorset, UK and Chemos GmbH, Re-
gensburg, Germany) with validation against the National
Institute of Standards and Technology standard reference
material 968d for fat-soluble vitamins, carotenoids, and
cholesterol in human serum. In-house quality control sam-
ples were also included in every run. The inter-assay and
intra-assay coefficients of variation for vitamin A, E, and
the carotenoid assay were both ,15% [12].
2.3. Other variables
DNA extracted from the blood sample drawn enabled
APOE genotyping of participants by “Sequenom iPLEX
assay.” A family history of AD and all comorbid health con-
ditions were documented as present or absent as determined
by self-report or consultation of medical notes. Smoking his-
tory was measured as a cumulative dose in pack-years.
2.4. Statistical analysis
Summary statistics for continuous variables and fre-
quencies and relative frequencies by group were calculated.
Independent t-tests (for continuous variables) or chi-square
tests (for categorical variables) were used to compare partic-
ipant characteristics between cases and controls. Pearson’s
correlation coefficients were performed to identify
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associations between cognitive indices with age and other
continuous variables.
Logistic regression models with dementia status (AD
or control) as the outcome and levels of serum levels of
vitamins A and E and the carotenoids entered as contin-
uous explanatory variables were used to calculate odds
ratios (ORs) for AD and 95% confidence interval (95%
CI), per unit increase in the serum levels of vitamins A
and E and the carotenoids. These ORs were calculated
before and after adjustment for confounders. In the
adjusted analysis, variables were eligible for inclusion
in the final logistic regression model if a significant asso-
ciation was found (P , .05) on univariate analysis or if
there was sufficient prior plausibility for their association
with AD. To determine the final model, a backward selec-
tion procedure was conducted and only variables that
were significantly associated with the dependent variable
(AD) were retained. Following this procedure, the final
model, used to calculate adjusted ORs, contained age,
number of APOE ε4 alleles, systolic blood pressure
(SBP), smoking pack-years (calculated as the product of
total years and average cigarettes per day), and
educational attainment (recorded as leaving school before
age 14). All statistical analyses were performed
using IBM SPSS statistics version 23 (IBM Corp., Ar-
monk, NY).
A sensitivity analysis was performed in cases only to
investigate the associations between cognitive indices of dis-
ease severity (MMSE) and serum antioxidants. Multiple
linear regression was used with serum antioxidants as the
outcome and MMSE as an exploratory variable along with
age, number of APOE ε4 risk alleles, SBP, smoking status,
and educational attainment.
3. Results
Demographic and clinical characteristics of the study
population (n5 559) are presented in Table 1 for both cases
(n 5 251) and controls (n 5 308). AD patients were more
likely to be older than controls (80.2 vs. 76.5 years), with
at least one APOE ε4 allele (69% vs. 25%). There were no
significant differences in gender between cases and controls,
with males constituting 36% of cases and 39% of controls.
Cases with AD had a significantly lower MMSE score
(18.0 vs. 28.8) and SBP (134 mm Hg vs. 144 mm Hg)
compared to control subjects. Markedly higher proportions
of patients with AD had left school at 14 years of age
(58% vs. 45%) compared to cognitively intact controls.
Furthermore, on average, patients with AD had accumulated
twice as many smoking pack-years as participants in the con-
trol group (17.7 vs. 10.0 pack-years; P , .01). The AD pa-
tients and the control subjects had similar disease burden
beyond AD diagnosis. A significantly greater proportion of
AD patients were more likely to be taking aspirin/clopidog-
rel (48% vs. 39%; P 5 .02) than controls.
Univariate analyses of serum levels of vitamin A, E, and
serum carotenoids were available for 251 AD cases and
308 controls. Table 2 shows the associations between AD
and serum levels of the dietary antioxidants analyzed.
AD patients had significantly lower serum levels of retinol
(P 5 .02), a-tocopherol, lutein, zeaxanthin, b-cryptoxan-
thin, a-carotene, b-carotene, and lycopene (P , .001)
compared to controls. By contrast, the mean serum level
of the vitamin E compound, g-tocopherol, was significantly
higher among AD cases compared to cognitively intact
controls (P , .001). Of interest, a 1 mmol/L increase in
g-tocopherol resulted in a 19% increase in risk associated
with AD (OR per mmol/L increase, 1.19 [CI: 1.10–1.30]),
whereas all other antioxidant vitamins and carotenoids
analyzed were negatively correlated with AD. With the
exception of retinol (OR per mmol/L increase, 0.68 [CI:
0.44–1.07]), all associations remained significant after
adjustment for age, APOE ε4 SBP, smoking status, and
educational attainment (Table 2). Higher levels of
g-tocopherol remained a significant predictor of increased
AD risk in the adjusted analyses (OR per mmol/L increase,
Table 1
Summary statistics of subject characteristics
Characteristic All (N 5 559) Control (n 5 308) Cases (n 5 251) P-value
Mean age, years (SD) 78.1 (7.4) 76.5 (6.7) 80.2 (7.7) ,.001
Male, n (%) 216 (38) 125 (39) 91 (36) .22
Mean MMSE (SD) 24.4 (6.8) 28.8 (1.2) 18.0 (6.5) ,.001
Presence of E4 allele, n (%) 240 (42) 71 (25) 169 (69) ,.001
Mean systolic blood pressure, mm Hg (SD) 139 (18) 144 (18) 134 (18) ,.001
Education—left school at 14 years, n (%) 274 (48) 138 (45) 136 (58) ,.01
Never smoked, n (%) 321 (59) 191 (62) 130 (54) .12
Diabetes mellitus, n (%) 59 (10) 37 (12) 22 (9) .17
Hypertension, n (%) 221 (391) 131 (43) 90 (38) .14
Cardiovascular disease, n (%) 129 (23) 76 (25) 53 (22) .27
Cerebrovascular disease, n (%) 70 (12) 38 (12) 32 (13) .42
Hypercholesterolemia, n (%) 216 (38) 124 (41) 92 (39) .37
Aspirin/clopidogrel, n (%)* 229 (40) 116 (39) 113 (48) .02
Abbreviations: SD, standard deviation; MMSE, Mini–Mental State Examination.
*Medications taken with a frequency .5%.
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1.17 [CI: 1.05–1.31]). The effect estimates in the adjusted
analyses were unchanged for a-tocopherol, lutein, and
b-carotene, identifying significant negative associations
with ORs of 0.92, 0.98, and 0.99, respectively, equating
to an 8%, 2%, and 1% reduction in risk of AD per unit in-
crease in serum concentration.
The inverse associations observed between serum levels
of zeaxanthin, b-cryptoxanthin, a-carotene, and lycopene
and AD risk were attenuated but remained significant in
the adjusted analyses. Lower serum levels of zeaxanthin
(OR per mmol/L increase, 0.92 [CI: 0.88–0.96]), b-cryptox-
anthin (OR per mmol/L, 0.96 [CI: 0.93–0.98]), a-carotene
(OR per mmol/L increase, 0.98 [CI: 0.96–0.99]), and lyco-
pene (OR per mmol/L increase, 0.32 [CI: 0.16–0.65]) were
observed in those with AD.
In a sensitivity analysis of cases only to assess antioxidant
associations with AD severity, only serum lutein was associ-
ated with MMSE score (serum lutein increased by
0.765 nmol/L [CI: 0.098–1.433; P 5 .03] per unit increase
in MMSE score; Table 3).
4. Discussion
This is one of the largest case-control studies to
compare serum levels of dietary antioxidants between sub-
jects with AD and cognitively intact controls. Our study
has shown that patients with AD have significantly lower
serum levels of retinol, a-tocopherol, and the six caroten-
oids measured. Moreover, our findings support the previous
evidence on the potential role of vitamins and carotenoids
as antioxidants within AD etiology and may reflect a
reduction in defenses against oxidative damage among
patients.
Before considering the potential impact of our findings
for future research in the area, the study had a number of lim-
itations for consideration. First, there may be residual con-
founding factors not measured in our sample that influence
serum antioxidant status but which have not been controlled
for in our data. Unfortunately, the most obvious omissions
are measurements of energy intake and supplement use
among participants. Taking these both in turn, undernutri-
tion/low energy intake could be determined via anthropo-
metric measures such as BMI. In addition, food diaries or
24-hour recalls could estimate energy intake and supplement
use but may be of limited value due to recall bias in those
with AD. Additional information on dietary intake would
also have proven beneficial in ascertaining whether reduced
dietary intake of carotenoids and vitamins occurred as a
result of cognitive decline or whether increased antioxidant
turnover due to elevated levels of oxidative stress manifests
in the compromised antioxidant status of AD patients. Simi-
larly, without sufficient knowledge regarding supplement
use among participants, it is difficult to draw strong conclu-
sions from the relationships observed. Without a reliable
measurement of these factors, our findings related to serum
micronutrient deficiency could potentially be confounded.
Second, the causal and temporal relationships between
the deficiency in serum antioxidants and AD cannot be deter-
mined due to the cross-sectional nature of our study. There is
evidence to support the hypothesis that lower levels of
Table 2
Serum antioxidant associations in subjects with Alzheimer’s disease and controls
Antioxidant
All (N 5 559) Controls (n 5 308) Cases (n 5 251)
Unadjusted odds ratio (CI) Adjusted odds ratio (CI)*Mean (SD) Mean (SD) Mean (SD)
Retinol (mmol/L) 1.51 (0.66) 1.57 (0.78) 1.44 (0.47) 0.65 (0.45–0.93) 0.68 (0.44–1.07)
g-Tocopherol (mmol/L) 4.49 (2.18) 4.14 (1.99) 4.92 (2.32) 1.19 (1.10–1.30) 1.17 (1.05–1.31)
a-Tocopherol (mmol/L) 17.7 (8.5) 19.1 (10.2) 16.0 (5.3) 0.92 (0.90–0.95) 0.92 (0.88–0.96)
Lutein (mmol/L) 48.5 (28.5) 53.3 (30.2) 42.5 (25.0) 0.98 (0.98–0.99) 0.98 (0.97–0.99)
Zeaxanthin (mmol/L) 12.2 (6.99) 13.7 (7.65) 10.3 (5.54) 0.90 (0.87–0.93) 0.92 (0.88–0.96)
b-Cryptoxanthin (mmol/L) 15.2 (12.9) 17.8 (14.3) 11.9 (10.0) 0.95 (0.94–0.97) 0.96 (0.93–0.98)
a-Carotene (mmol/L) 23.6 (19.1) 26.9 (20.9) 19.6 (15.6) 0.97 (0.96–0.99) 0.98 (0.96–0.99)
b-Carotene (mmol/L) 123 (94.1) 139 (105) 103 (74.9) 0.99 (0.99–0.99) 0.99 (0.99–0.99)
Lycopene (mmol/L) 0.44 (0.54) 0.54 (0.60) 0.32 (0.43) 0.29 (0.17–0.49) 0.32 (0.16–0.65)
Abbreviations: SD, standard deviation; CI, confidence interval.
*Multiple logistic regression analysis adjusted for age (years), number of APOE ε4 alleles, smoking (pack-years), systolic blood pressure, education (leaving
school before 14 years).
Table 3
Sensitivity analysis of serum antioxidant levels by MMSE score in






Retinol (mmol/L) 20.001 20.014, 0.012 .93
g-Tocopherol (mmol/L) 0.019 20.041, 0.079 .53
a-Tocopherol (mmol/L) 0.037 20.089, 0.163 .56
Lutein (mmol/L) 0.765 0.098, 1.433 .03
Zeaxanthin (mmol/L) 0.102 20.043, 0.246 .17
b-Cryptoxanthin (mmol/L) 0.101 20.165, 0.367 .45
a-Carotene (mmol/L) 0.083 20.354, 0.520 .71
b-Carotene (mmol/L) 1.492 20.532, 3.516 .15
Lycopene (mmol/L) 0.001 20.008, 0.009 .92
Abbreviation: MMSE, Mini–Mental State Examination.
*The average increase in each serum antioxidant level per unit increase in
MMSE score. Adjusted for age (years), number of APOE ε4 alleles, smok-
ing (pack-years), systolic blood pressure, education (leaving school before
14 years).
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plasma antioxidants may manifest as a consequence of AD
[13]. However, current research suggests these findings
may have been influenced by reverse causation bias. The ev-
idence from a meta-analysis by Da Silva et al. discounts the
contribution of energymalnutrition to the pro-oxidative state
suggesting oxidative stress and subsequent depletion of
serum antioxidants is an early event in AD that occurs in
the presymptomatic stage of MCI [14]. Within the confines
of our cross-sectional study, the sensitivity analysis we per-
formed in cases only supports the findings of Da Silva and
colleagues insofar as only serum lutein was significantly
depleted with increasing disease severity, as determined by
MMSE score (Table 3). Further support by experimental
studies in transgenic mice found markers of oxidative stress
that preceded the appearance of the hallmarks of the disease
[15]. Because of these inconsistencies, a large, prospective
study would help clarify the precise interrelationship and na-
ture of this association.
Finally, other methodological issues may further compli-
cate the interpretation of our data. The opportunistic
approach of clinic-based sampling offered the best chance
of recruiting a sufficient number of subjects for the study
to be adequately powered, while avoiding systematic bias,
although this approach may have inhibited subject demo-
graphics and limited the generalizability of conclusions.
The results of any association study are vulnerable to ascer-
tainment bias. For example, those with poor dietary intake
may have been overrepresented if they were more likely to
be having difficulties with activities of daily living and there-
fore seek medical help. Future studies should aim to adopt a
truly random approach to recruitment, using population
census records for identifying controls and a comprehensive
AD patient database to sample cases. Equally, recall bias
may have led to underestimates of the prevalence of con-
founding factors among cases, despite a carer being present
and medical notes consulted as needed.
Although AD cases were significantly older than cogni-
tively intact controls, no significant change in the effect es-
timates was observed when these were adjusted for age. The
standard deviation for the meanMMSE score in AD patients
was 5 times greater than that of the control group, indicative
of the wide range of AD severity categorized by the MMSE
included in our study.
The main classes of exogenous antioxidants include
polyphenols, vitamins, and carotenoids. The carotenoid
class can be further subdivided into carotenes and xantho-
phylls. The subclass of carotenes consists of a-carotene, b-
carotene, and lycopene, whereas the xanthophylls include
lutein, zeaxanthin, and b-cryptoxanthin. Lycopene is a
naturally occurring red pigment found in tomatoes and is
the most predominant carotenoid, accounting for more
than half of total carotenoid in human serum [16]. Because
of its unsaturated chemical structure, lycopene has the most
powerful antioxidant properties among all serum caroten-
oids with an oxygen quenching ability twice that of b-caro-
tene and 10 times higher than a-tocopherol [17].
Consequently, lycopene demonstrated the largest effect
size observed, by far, of all the antioxidants considered
within our study.
Two isomers of the xanthophyll subclass, lutein and zeax-
anthin, are particularly common in dark green leafy vegeta-
bles and corn and are present in high concentrations within
the brain and retina where they exert neuroprotective and
antioxidant effects. In addition, they have been reported to
enhance gap junction communication in neurons [18].
Another study by Min and colleagues reported high serum
concentrations of lutein and zeaxanthin associated with
reduced risk of AD-related mortality in adults [19]. Our
study provides further support of the protective effect of
serum lutein and zeaxanthin against oxidative damage, given
the subtle reductions in risk observed in cognitively intact
controls of 2% and 8%, respectively, for each mmol/L unit
increase.
There has been limited research investigating the mech-
anisms that underlie the inverse associations between
serum antioxidant levels and AD risk [4,5]. However,
given the antioxidant deficiency observed among AD
patients, the evidence suggests these micronutrients are
involved in the mediation of oxidative stress leading to
neurodegeneration. The biological plausibility may be
explained in part by the protective effects antioxidants
exert against damage from reactive oxygen species.
However, in the absence of evidence of a causal
relationship between low serum antioxidant levels and
increased AD risk, we must exert caution in our
interpretation as we cannot exclude reverse causality.
Vitamin E is one of the principal vitamins with antioxida-
tive properties and is a collective term used for eight natu-
rally occurring compounds consisting of four tocopherols
and four tocotrienols. The isoforms, a-tocopherol and
g-tocopherol, are the most abundant in both diet and tissues.
Typically, an American diet may provide twice as much g as
a-tocopherol, due to different compositions of dietary fats
[20]. As such, the higher concentration of g-tocopherol
observed in the AD group could result from differential di-
etary intake or as a consequence of disturbed tocopherol
metabolism and antioxidant capacity in patients with AD
[20–22].
Evidence suggests thatg-tocopherol ismore effective than
a-tocopherol in reducing oxidative damage, scavenging free
radicals, and exhibiting anti-inflammatory effects [23–25].
This evidence may provide biological plausibility for the
opposing associations of both isoforms with AD risk
observed in our study. An antagonistic interaction between
both isoforms was previously reported where elevated
levels of a-tocopherol were associated with reduced
g-tocopherol functionality in serum [26]. g-Tocopherol
levels in the serum of AD patients may vary depending on
the severity of the serum depletion of a-tocopherol and its
subsequent bioavailability which highlights a significant
concern of trials investigating vitamin E supplementation in
AD using a-tocopherol alone [27].
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In addition, the opposing associations we observed for
a- and g-tocopherol may highlight a potential limitation
of previous vitamin E trials, as proposed by La Fata
et al. in a recent systematic review of vitamin E trials in
AD [28]. They identified reporting inconsistencies
regarding the specification of the form of vitamin E admin-
istered across intervention studies and postulated on the po-
tential impact this may have on trial outcomes. Two studies
by Dysken et al. [27] and Sano et al. [29] administered the
same isoform of vitamin E, namely that of a-tocopherol,
and subsequently measured serum levels of the isoform
across all subjects. The congruency in both the vitamin E
form administered and outcome measures recorded enables
direct comparisons of both studies. Conversely, the iso-
forms used in two additional RCTs of vitamin E in AD
were not specified [30,31]. Our data indicate opposing
effects of vitamin E isoforms in AD, highlighting the
necessity for a more standardized approach to trials in
relation to the isoform of vitamin E administered to more
accurately determine the true effect it may exert on the
onset and progression of AD from mild to severe forms
[32]. Our results may offer some understanding of the
null results reported from previous trials whereby opting
to supplement the wrong isoform in an unbalanced mono-
therapy overlooked the antioxidant effects of other forms
of tocopherol as well as the synergistic effect with other di-
etary antioxidants in ROS removal [33]. We suggest these
admissions should form important learning points in the re-
structuring of future trials of dietary antioxidant supple-
mentation.
An alternative approach involving the supplementation
of a specific combination of antioxidants and micronu-
trients known to be deficient in AD patients has been
explored in two RCTs using a medical nutrition drink
[34,35]. The multicounty trials demonstrated significant
improvements in memory domain scores in drug-na€ıve
patients with mild AD. These findings mark a critical
step toward achieving more meaningful improvements in
neurological domains in shifting from a target-based to a
more balanced approach, in addressing antioxidant defi-
ciencies.
A balanced approach to supplementation is further
supported by the outcomes of The Cashe County Trial
which examined the degree to which vitamin supple-
ments, namely vitamins E and C, was associated with
occurrence of AD [36]. The authors, Zandi et al., found
the use of vitamin E and C supplements in combination
to be associated with reduced incidence of AD thus
providing further support for the synergistic benefit of a
combined supplementation approach. Reviewing these
findings in the context of our own results highlights the
importance of an informed choice of micronutrients for
future clinical trials so that synergetic effects are maxi-
mized and the antagonist effects of specific vitamin E iso-
forms are elucidated.
Themajor strengths of our study were the large number of
subjects, the range of severity of AD cases included, and the
number of potentially confounding factors considered. Our
study focused solely on AD to the exclusion of other demen-
tia subtypes, such as vascular dementia. In addition, micro-
nutrient serum measurement is an objective determinant
independent of the dietary intake estimates remembered
over a period.
Our findings are of major public health importance as the
search for modifiable risk factors takes precedence in the
absence of preventative or curative treatments. Identifying
individuals at increased future risk of developing AD, and
detecting adverse risk at the earliest stages, may be most
effective in delaying disease progression and preserving
function within the aging brain.
However, there is still insufficient evidence regarding a
causal relationship between low antioxidants level and
development of AD. The replication of our findings in a
more robust study design could allow for the introduction
of an inexpensive nutritional intervention that could be im-
plemented via dietary or supplementary approaches. Future
research should consider a wider spectrum of antioxidants or
indeed the various forms of vitamin E through expanded an-
alyses to include hydrophilic antioxidants and other sub-
classes such as flavonoids, to further improve our
understanding in this area.
In conclusion, this is one of the largest case-control
studies to demonstrate lower serum antioxidant levels
among patients with AD compared to cognitively intact con-
trols. The opposing effects with AD risk demonstrated by the
two isoforms of vitamin E highlight the complexity of the as-
sociations between antioxidants and disease and the need to
consider issues like isoform, dose, dietary intake, and
possible interactions when designing clinical trials. More-
over, it provides arguments for the remodeling of previous
approaches to address antioxidant imbalance in support of
possible interactions between various dietary antioxidants.
Future large-scale, longitudinal studies and clinical trials
that consider changes in antioxidant status with declining
cognitive function are required. Given the potential implica-
tions of nutritional status in AD etiology, the therapeutic po-
tential of nutrition warrants further investigation and may
prove beneficial in AD management.
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RESEARCH IN CONTEXT
1. Systematic review: We reviewed existing literature
investigating associations between serum dietary an-
tioxidants and Alzheimer’s disease (AD). Despite
numerous studies, findings reported have been incon-
sistent partly through smaller sample sizes in a
limited number of antioxidants. We measured serum
antioxidants in 559 samples from a prevalent case-
control study that compared Alzheimer’s disease to
cognitively intact controls.
2. Interpretation: We report lower serum levels of
retinol, a-tocopherol, and six carotenoids in partici-
pants with AD, which all remained significant after
adjustment for recognized AD risk factors, with the
exception of retinol. In contrast, g-tocopherol levels
were significantly higher in those with AD. Our re-
sults are consistent with hypotheses supportive of a
neuroprotective role of dietary antioxidants.
3. Future directions: Our data provide support for
serum antioxidants in AD. Additional analyses that
expand on the subclasses and isoforms of dietary an-
tioxidants reported are required to better inform
nutritional interventions as a potential therapeutic
strategy for AD.
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